Johnson & Johnson vaccine was 72 percent effective in U.S. trial-politico: Johnson & Johnson's coronavirus vaccine was 72 percent effective in the first data from a late-stage U.S. trial, the company said Friday. But the vaccine's efficacy fell to 52 percent against a virus variant first identified in South Africa.
